interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Crinecerfont

Generic competition · all medicines · read 12 November 2026

Is there a generic of Crinecerfont, and who makes it?

Crinecerfont appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Crinecerfont2 dosage-form groups in the Orange Book
0generic makers listed
  1. Crinecerfont appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Crenessity. No generic is listed as marketed.

20202025203020352040204501brand 2024data datePatent 10905690 listed to expire 21 January 2035Patent 11311544 listed to expire 21 January 2035Patent 11730739 listed to expire 21 January 2035Patent 12128033 listed to expire 9 June 2041Patent 12582634 listed to expire 12 January 2043Exclusivity NCE to 13 December 2029Exclusivity ODE-503 to 13 December 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 13 December 2029Exclusivity NCE Crenessity
  • 13 December 2031Exclusivity ODE-503 Crenessity
  • 21 January 2035Patent 10905690
  • 21 January 2035Patent 11311544
  • 21 January 2035Patent 11730739
  • 9 June 2041Patent 12128033 drug substance
  • 12 January 2043Patent 12582634 drug substance

Solution, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Crenessity. No generic is listed as marketed.

20202025203020352040204501brand 2024data datePatent 10905690 listed to expire 21 January 2035Patent 11311544 listed to expire 21 January 2035Patent 11730739 listed to expire 21 January 2035Patent 12128033 listed to expire 9 June 2041Patent 12582634 listed to expire 12 January 2043Exclusivity NCE to 13 December 2029Exclusivity ODE-503 to 13 December 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 13 December 2029Exclusivity NCE Crenessity
  • 13 December 2031Exclusivity ODE-503 Crenessity
  • 21 January 2035Patent 10905690
  • 21 January 2035Patent 11311544
  • 21 January 2035Patent 11730739
  • 9 June 2041Patent 12128033 drug substance
  • 12 January 2043Patent 12582634 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.